Abraxane and Cholestasis - a phase IV clinical study of FDA data

Summary:

Cholestasis is reported as a side effect among people who take Abraxane (paclitaxel), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Gemcitabine, and have Pancreatic carcinoma metastatic.

The phase IV clinical study analyzes which people have Cholestasis when taking Abraxane. It is created by eHealthMe based on reports of 19,123 people who have side effects when taking Abraxane from the FDA, and is updated regularly.

What is Abraxane?

Abraxane has active ingredients of paclitaxel. It is often used in breast cancer metastatic. eHealthMe is studying from 19,196 Abraxane users. Check the latest studies of Abraxane.

What is Cholestasis?

Cholestasis (a condition where bile cannot flow from the liver to the duodenum) is found to be associated with 1,034 drugs and 1,812 conditions by eHealthMe. Check the latest studies of Cholestasis.

On Aug, 01, 2026

19,123 people reported to have side effects when taking Abraxane.
Among them, 27 people (0.14%) have Cholestasis.

Among these 27 people:

How long have people been on Abraxane when they have Cholestasis? *

What is the gender of people who have Cholestasis when taking Abraxane? *

female: 57.69 %
male: 42.31 %

What is the age of people who have Cholestasis when taking Abraxane? *

What are other drugs people take besides Abraxane? *

What are other side effects people have besides Cholestasis? *

Hepatocellular Injury (liver injury): 7 people, 25.93%
Hyperbilirubinaemia (excess of bilirubin in the blood): 4 people, 14.81%
Jaundice - Yellow Skin (a yellowish pigmentation of the skin): 4 people, 14.81%
Thrombocytopenia (decrease of platelets in blood): 4 people, 14.81%
Liver Disorder (liver diseases): 3 people, 11.11%
General Physical Health Deterioration (weak health status): 3 people, 11.11%
White Blood Cell Count Decreased: 3 people, 11.11%
Hepatic Cyst: 2 people, 7.41%
Blood Creatinine Decreased: 2 people, 7.41%
Haematocrit Decreased: 2 people, 7.41%

What are the existing conditions these people have? *

Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 8 people, 29.63%
Adenocarcinoma Pancreas (cancer of pancreas): 4 people, 14.81%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 14.81%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 11.11%
Diabetes: 3 people, 11.11%
High Blood Pressure: 3 people, 11.11%
Nausea (feeling of having an urge to vomit): 3 people, 11.11%
Hypertensive Heart Disease: 2 people, 7.41%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 7.41%
Leukopenia (less number of white blood cells in blood): 2 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Abraxane and have Cholestasis?

- Check whether Cholestasis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abraxane:

Abraxane (19,196 reports)

Cholestasis treatments and more:

Cholestasis (23,731 reports)

Browse all side effects of Abraxane:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cholestasis:

Cholestasis (1,034 drugs)

Browse all the conditions that are associated with Cholestasis:

Cholestasis (1,812 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paclitaxel (the active ingredients of Abraxane) and Abraxane (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.